EUCTR2005-004856-11-DE进行中（未招募）不适用
Symptom reduction in hospitalized patients suffering from symptomatic non-erosive or erosive gastroesophageal reflux disease treated with pantoprazole 20 or 40 mg o.d. for 7 days - PROFI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent by the patient for study participation, prior to protocol specific procedures
- •- Inpatients of at least 18 years of age (hospitalization during the entire study period is mandatory)
- •- Symptomatic (heartburn, acid regurgitation or dysphagia for at least 1 day since admission to the hospital) non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD, LA grade A-D)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Signs, indicating other gastrointestinal diseases:
- •- Known Zollinger-Ellison syndrome or other gastric hypersecretory condition
- •- Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy)
- •- On initial endoscopy, presence of obstructive esophageal strictures, Schatzki’s ring, esophageal diverticula, esophageal varices, achalasia or Barrett‘s esophagus with known high-grade dysplasia or longer than 3 cm
- •- Acute peptic ulcer and/or ulcer complications
- •- Pyloric stenosis
- •- Known inflammatory bowel diseases
- •Other concomitant diseases:
- •- Severe or unstable cardiovascular (e.g. severe angina pectoris, postmyocardial infarction and ventricular extrasystoles), pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant as considered by the investigator
- •- Malignant disease of any kind during the previous 5 years except for successfully treated skin (basal or squamous cell) cancer
- •- Tendency to react allergically to drugs, especially with known hypersensitivity to one of the compounds of the study medication
- •- Alcohol, drug or medication abuse within the past year
- •- Abnormal laboratory parameters and vital signs considered as clinically relevant by the investigator and not explainable by medical history
- •- Severe psychiatric or neurologic disorders as considered by the investigator
- •Special restrictions for female patients:
- •- Pregnant or nursing female patients
- •- Female patients of childbearing potential, who are not using and not willing to use medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless they are surgically sterilized / hysterectomized or any other criteria considered sufficiently reliable by the investigator in individual case
- •Previous medication:
- •- Proton pump inhibitors (PPIs) during the last 3 days before intake of study medication
- •- H2-receptor antagonists or prokinetics : stop at Visit V0
- •- Sucralfate, bismuth preparations or other substances, which may have an influence on the relief of acid-related symptoms: stop at Visit V0
- •- Any medication for the purpose of the eradication of H. pylori during the last 28 days before intake of study medication
- •Concomitant medication
- •- Proton pump inhibitors (PPIs, except study medication), H2-receptor antagonists, antacids, prokinetics, sucralfate, bismuth preparations or other substances, which may have an influence on the relief of acid-related symptoms
- •- Onset or change in the first two days of the study of systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors
- •- Ketoconazole or other drugs with pH-dependent absorption
- •- Proton pump inhibitors (PPIs) in combination with antibiotics for the purpose of the eradication of H. pylori
- •- Patients who are expected to be non-compliant and/or not co-operative
- •- Participation in a clinical study within the last 30 days prior to the start of the study
- •- Patients who have participated already in this study
- •- Patients who are employees at the investigational site, relative or spouse of the investigator
- •- Any donation of germ cells, blood, organs, or bone marrow during the course of the study
- •- Patients who are not contractual
研究者
相似试验
招募中
Unknown
Observational study of hospitalized patients with heart failure at the Japanese Red Cross Wakayama Medical Centerheart failureJPRN-UMIN000053982Japanese Red Cross Wakayama Medical Center1,000
已完成
不适用
Effect of PHARMacological treatment in hospitalized patients with Heart FailureHeart failureJPRN-UMIN000043293Department of Medical Science and Cardiorenal Medicine, Yokohama City University254
已完成
3 期
COVID-19: Reducing Symptoms and Hospitalization rates by use of Azelastine Nasal spray in patients suffering from COVID-19 in Early stagesTreatment of COVID-19 patientsDRKS00028829RSAPHARM Arzneimittel GmbH272
尚未招募
不适用
The effects of Posture and Continuous Positive Airway Pressure (CPAP) on lung function in patients recovering from an acute exacerbation of heart failureCardiovascular - Other cardiovascular diseasesRespiratory - Other respiratory disorders / diseasesHeart FailureACTRN12610000556044Professor Matthew Naughton100
尚未招募
不适用
Association of physical symptoms during hospitalization after severe illness with walking ability at dischargecritically ill patientsJPRN-UMIN000040135agasaki University hospital200